Table 1 Demographics and clinical characteristics (Figs. 1, 2 and 3)

Age

Years

58.5 (9.5)

57.3 (9.6)

59.8 (8.4)

53.1 (9.0)

58.3 (10.0)

Gender

Male

82 (77%)

54 (75%)

25 (76%)

11 (73%)

85 (78%)

Female

24

18

8

4

24

Clinical Stage

0/1

13

8

-

7

13

2

9

7

1

-

9

3

16

12

5

3

17

4

68 (64%)

45 (63%)

27 (82%)

5 (33%)

70 (64%)

T stage

T1

32

23

6

11

33

T2

25

19

11

1

26

T3

18

12

7

2

18

T4

28

16

8

1

29

X

3

2

1

-

3

N stage

N0

40

26

3

11

40

N1

8

5

3

-

10

N2

53

39

27

4

54

N3

5

2

-

-

5

M stage

M1

1

1

-

1

1

Disease Site

Larynx

26

13

4

3

26

Oral Cavity

21

17

1

7

22

Oropharynx

53

38

27

5

55

Nasopharynx

1

1

-

-

1

Hypopharynx

2

2

-

-

2

Unknown primary

3

1

1

-

3

Initial Treatment

Chemoradiotherapy

50

33

33

-

52

Chemotherapy

2

1

-

-

2

Radiotherapy

7

4

-

-

7

Surgery

43

30

-

15

44

Unknown

4

4

-

-

4

ACE Comorbidities Score

None

31

23

10

4

32

Mild

52

32

17

8

54

Moderate

16

12

5

3

16

Severe

7

5

1

-

7

BMI

Underweight (< 18.5)

3

2

-

-

3

Normal (15.5–24.9)

31

19

6

6

32

Overweight (25–29.9)

41

30

15

6

42

Obese (30 +)

31

21

12

3

32

HPV status (among OP only)

Positive

42 (79%)

31 (82%)

22 (81%)

3 (60%)

44 (80%)

Drinker

Never

5

4

1

1

5

Current

77

56

25

12

80

Former (quit > 12 months)

24

12

7

2

24

Smoker (cigarettes)

Never

26

19

7

4

27

Current

46

36

14

9

47

Former (quit > 12 months)

34

17

12

2

35

First Recurrence Pattern

Persistent Disease

3

2

0

1

3

Locoregional

7

4

1

2

8

Distant

6

4

3

-

6

Locoregional + Distant

6

6

4

-

6